Cutaneous sclerosis

Common Name(s)

Cutaneous sclerosis

Cutaneous sclerosis is a rare disease in which the skin develops thicker layers and or scars. While this condition primarily affects the skin, these symptoms can also be found in other tissues and joints. Individuals with cutaneous sclerosis have an overproduction of collagen (a protein needed for connective tissue) by the skin cells during the healing process. Although the cause is not always known, it is seen in 10-20% of persons with graft-versus-host disease (please also visit: graft versus host disease.) which occurs after a transplant of cells, tissues, or organs.

Symptoms of cutaneous sclerosis include visible changes to the skin where is looks thick, feels tight and does not move easily. The diagnosis is confirmed by taking a skin sample and studying it under a microscope. Cutaneous sclerosis is often treated by oral steroids and immunosuppressive treatments to decrease the activity of the immune system (your body’s response to infection). Other more specialized treatments are sometimes needed if these fail. If you or a family member has been diagnosed with cutaneous sclerosis, talk with your doctor or specialist about the most current treatment options. There are support groups for more general scleroderma diagnosis, which provide additional resources.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous sclerosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous sclerosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Cutaneous sclerosis" returned 79 free, full-text research articles on human participants. First 3 results:

Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report.
 

Author(s): Loukman Omarjee, Cedric Fontaine, Guillaume Mahe, Vincent Jaquinandi

Journal: Medicine (Baltimore). 2017 Jun;96(25):e6988.

 

Sildenafil, a phosphodiesterase-5-inhibitor and Bosentan, an endothelin-1-receptor antagonist combined therapy could have beneficial effect in systemic sclerosis (SSc) patients with peripheral artery disease.

Last Updated: 22 Jun 2017

Go To URL
A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter?
 

Author(s): He Liu, Yong Hou, Qing-Li Zhu, Dong Xu, Liang Wang, Jian-Chu Li, Yu-Xin Jiang, Qian Wang, Meng-Tao Li, Feng-Chun Zhang, Xiao-Feng Zeng

Journal:

 

To evaluate the usefulness of skin ultrasound and acoustic radiation force impulse (ARFI) quantification in diffuse cutaneous systemic sclerosis (dcSSc).

Last Updated: 24 Mar 2017

Go To URL
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
 

Author(s): Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton

Journal: Ann. Rheum. Dis.. 2017 Jul;76(7):1207-1218.

 

The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches.

Last Updated: 11 Feb 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Cutaneous sclerosis" returned 3 free, full-text review articles on human participants. First 3 results:

Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.
 

Author(s): Michael A Cardis, Cynthia Marie Carver DeKlotz

Journal: Arch. Dis. Child.. 2017 Sep;102(9):858-863.

 

Tuberous sclerosis complex (TSC) is a multisystem genetic disorder stemming from unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple organs. TSC-related skin lesions often develop early in life and can be disfiguring, ...

Last Updated: 29 Mar 2017

Go To URL
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
 

Author(s): Dinesh Khanna, Veronica J Berrocal, Edward H Giannini, James R Seibold, Peter A Merkel, Maureen D Mayes, Murray Baron, Philip J Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W Simms, Yannick Allanore, Christopher P Denton, Oliver Distler, Sindhu R Johnson, Marco Matucci-Cerinic, Janet E Pope, Susanna M Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U Wells, Daniel E Furst

Journal: Arthritis Rheumatol. 2016 Feb;68(2):299-311.

 

Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs).

Last Updated: 26 Jan 2016

Go To URL
[Efficacy of anti-thymocyte globulin and cyclosporin A combined therapy in aplastic anemia complicated with limited cutaneous systemic sclerosis].
 

Author(s): Eiichi Suematsu, Tomoya Miyamura, Kensaku Idutsu, Rumi Minami, Masahiro Yamamoto

Journal: Nihon Rinsho Meneki Gakkai Kaishi. 2005 Apr;28(2):99-103.

 

We reported here on a case of limited cutaneous systemic sclerosis (lcSSc) with aplastic anemia treated by anti-thymocyte globulin and cyclosporin A. The use of this therapy resulted not only in marrow recovery but also in resolution of the skin sclerosis. A 68 year-old woman was ...

Last Updated: 2 May 2005

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
 

Status: Not yet recruiting

Condition Summary: Diffuse Cutaneous Systemic Sclerosis

 

Last Updated: 1 Aug 2017

Go to URL
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
 

Status: Recruiting

Condition Summary: Scleroderma, Diffuse; Diffuse Cutaneous Systemic Sclerosis

 

Last Updated: 13 Jun 2016

Go to URL
Brentuximab Vedotin for Systemic Sclerosis
 

Status: Recruiting

Condition Summary: Diffuse Cutaneous Systemic Sclerosis; Scleroderma; dcSSc

 

Last Updated: 20 Sep 2017

Go to URL